Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus

Matthew Cagliostro, Prabhjot Hundal, Peter Ting, Sonika Patel, Sangita Sudarshan, Jordan Thomas, Kathleen Morris, Donna M. Mancini, Noah Moss, Anuradha Lala, Ashwin Ravichandran, Sumeet S. Mitter

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

SGLT-2 inhibitors have been shown to confer reduced risk of adverse cardiovascular events in patients with heart failure, and have also been studied preliminarily among heart transplant patients, with overall positive findings. Use of SGLT-2 inhibitors among patients with durable mechanical circulatory support has not been studied. Here we present our results from a combined retrospective cohort of LVAD patients on SGLT-2 inhibitors at two major academic centers, which showed a good safety profile but prompted questions for further investigation. We advocate for further research into the safety and impact of SGLT-2 inhibitors among LVAD patients.

Original languageEnglish
Article number100154
JournalAmerican Heart Journal Plus: Cardiology Research and Practice
Volume18
DOIs
StatePublished - Jun 2022

Keywords

  • Heart failure
  • Left ventricular assist device (LVAD)
  • SGLT2 inhibitors (SGLT2i)

Fingerprint

Dive into the research topics of 'Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this